Abstract
Introduction: Pemphigus vulgaris (PV) is a rare autoimmune blistering disease characterized by the formation of intraepithelial blisters caused by autoantibodies targeting desmosomal proteins, such as desmoglein 1 and 3. Although uncommon, its clinical severity is significant, especially because oral manifestations are often the first to appear and the most persistent. In this context, the dentist plays a crucial role in the early diagnosis of the disease. With the introduction of COVID-19 vaccines, sporadic reports have emerged of patients developing new-onset or reactivation of PV following immunization, raising hypotheses about a possible immunological correlation. Therefore, it is important to understand whether this association reflects causality or merely a temporal coincidence, contributing to clinical surveillance and appropriate management of susceptible patients. Objective: To analyze the relationship between vaccination against COVID-19 and the development or exacerbation of pemphigus vulgaris (PV), a rare autoimmune bullous disease, investigating the immunological mechanisms involved and highlighting the role of dentists in early identification. Methods: An integrative literature review was carried out in the PUBMED database between January and June 2024, studies including systematic reviews, case-control studies and meta-analyses published between 2021 and 2024, in Portuguese, English and Spanish, addressing post-vaccination PV. Of the 78 articles identified, 40 were selected, resulting in 17 articles included in the review. Results: PV, characterized by the formation of intraepithelial blisters due to autoantibodies, is rare, with an incidence of 1 to 5 cases per million per year. Reports indicate exacerbation of the disease after immunization against COVID-19, possibly due to molecular mimicry and inflammatory dysregulation. However, most patients with autoimmune bullous diseases did not show significant worsening after booster doses. Conclusion: Although the association between PV and COVID-19 vaccination is rare, continued surveillance is essential. Dentists have a crucial role in the early identification of the disease.
References
AKOGLU G. Pemphigus vulgaris after SARS‐CoV‐2 vaccination: a case with new‐onset and twocases with severe aggravation. Dermatologic Therapy, 2022; 35(5): e15396.
CALABRIA E, et al. Autoimmune mucocutaneous blistering diseases after SARS-Cov-2 vaccination: a case report of pemphigus vulgaris and a literature review. Pathology-Research and Practice, 2022; 232: 153834.
DAGISTAN S, et al. Oral pemphigus vulgaris: a case report with review of the literature. Journal of Oral Science, 2008; 50(3): 359-362.
DAMIANI G, et al. The first dose of COVID‐19 vaccine may trigger pemphigus and bullous pemphigoid flares: is the second dose therefore contraindicated?. Journal of the European Academy of Dermatology and Venereology, 2021; 35(10): e645.
DE MEDEIROS VLS, et al. Pemphigus vulgaris after COVID-19: a case of induced autoimmunity. SN Comprehensive Clinical Medicine, 2021; 3(8): 1768-1772.
HALI SRF, et al. Autoimmune bullous dermatosis following COVID-19 vaccination: a series of five cases. Cureus, 2022; 14(3).
HUANG X, et al. Pênfigo durante a epidemia de COVID-19: risco de infecção, respostas vacinais e estratégias de gestão. J Clin Med, 2022; 11(14): 3968.
IRIE K, YAMAMOTO T. Agravamento grave e possível desencadeamento de pênfigo vulgar após vacinação contra COVID-19: relato de dois casos. Anais Brasileiros de Dermatologia, 2024.
KASPERKIEWICZ M, et al. Safety of the COVID‐19 vaccine booster in patients with immunobullous diseases: A cross‐sectional study of the International Pemphigus and Pemphigoid Foundation. Journal of the European Academy of Dermatology and Venereology, 2023.
KASPERKIEWICZ M, WOODLEY DT. COVID-19 and autoimmune bullous diseases: Lessons learned. Autoimmunity Reviews, 2023; 22(4): 103286.
MARINOVIĆ B, et al. Pênfigo — o ponto crucial das clínicas, pesquisas e tratamentos durante a pandemia da COVID-19. Biomedicines, 2021; 9(11): 1555.
MARTORA F, et al. Pemphigus and Bullous Pemphigoid Following COVID-19 Vaccination: A Systematic Review. Viruses, 2024; 16(12): 1896.
NAJARY S, et al. A comprehensive review of oral microenvironment changes and orofacial adverse reactions after COVID‐19 vaccination: The good, the bad, and the ugly. Health Science Reports, 2024; 7(3): e1967.
NEVILLE B. Patologia oral e maxilofacial. 4ª ed. Rio de Janeiro: Elsevier, 2016; 928 p.
ONG SK, DARJI K, CHAUDHRY SB. Severe flare of pemphigus vulgaris after first dose of COVID-19 vaccine. JAAD Case Reports, 2022; 22: 50-52.
RISSO M, et al. Pênfigo vulgar: relato de caso clínico. RGO. Revista Gaúcha de Odontologia (Online), 2011; 59(3): 515-520.
SAFFARIAN Z, et al. De novo severe pemphigus vulgaris following SARS‐CoV‐2 vaccination with BBIBP‐CorV. Dermatologic Therapy, 2022; 35(6).
SINGH A, et al. Development of severe pemphigus vulgaris following ChAdOx1 nCoV‐19 vaccination and review of literature. Journal of Cosmetic Dermatology, 2022; 21(6): 2311-2314.
SOLIMANI F, et al. Development of severe pemphigus vulgaris following SARS‐CoV‐2 vaccination with BNT162b2. Journal of the European Academy of Dermatology and Venereology, 2021; 35(10): e649.
THONGPRASOM K, et al. Oral pemphigus after COVID‐19 vaccination. Oral Diseases, 2021.
WU, Po-Chien et al. New Onset and Exacerbation of Autoimmune Bullous Dermatosis Following COVID-19 Vaccination: A Systematic Review. Vaccines, v. 12, n. 5, p. 465, 2024.

This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2025 Humberto Calixto da Silva Neto, André André Lucas Almeida Jerônimo, Hudson Israel das Neves, João Henrique Martins Fernandes da Silva, José Abel Pessôa Neto, Raylana Vitória da Silva Vasconcelos, Rodrigo de Oliveira Borges, Sabrina Luany Santos Félix da Silva, Samantha Soares de Paula, Jackeline Maria da Silva